Drug intelligence / Profile preview

Myr-201

Development stage: Preclinical
Lead developer: Myrtelle
Modality: Gene Therapies
Administration: Subcutaneous

Overview

Myr-201 is a novel gene therapy candidate developed by Myrtelle for the treatment of autosomal recessive deafness 8 (DFNB8), a form of monogenic hearing loss. Myrtelle has partnered with Forge Biologics for the manufacturing of Myr-201 for clinical trials and potential commercial-stage production.

Targets

TMPRSS3 (Transmembrane protease serine 4)

Beyond the preview

Go deeper on Myr-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myr-201.

Explore the full profile